BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan launches nationwide initiative to promote gastric health and early detection of gastric cancer, Co-initiated by Mirxes Japan & Nagawa

July 24, 2025 | News

Mirxes Japan and Nagawa Pharmaceutical partner to build a comprehensive early cancer detection ecosystem in Japan.



A nationwide public health initiative focused on gastric health and early detection of gastric cancer has been launched by Japan's 93rd Prime Minister Yukio Hatoyama. The initiative will leverage GASTROClear™, a novel non-invasive microRNA-based blood test developed by Mirxes.

The launch of this nationwide public health initiative coincides with the launch of a strategic partnership between Mirxes Japan and Nagawa Pharmaceutical that aims to accelerate the development and deployment of Mirxes' early cancer screening solutions, and strengthen its brand recognition across Japan.

Singapore-headquartered Mirxes is deploying miRNA detection technology and the approved, clinically validated GASTROClear™ blood test to make the screening experience more comfortable and boost screening participation for the Japanese public through local presence as Mirxes Japan.

Co-initiated by Mr. Hatoyama, Mirxes Japan and Nagawa Pharmaceutical, the ambitious initiative will offer free screening to 10,000 residents across Japan, with a particular focus on senior citizens. This initiative aims to:

- Raise public awareness and improve gastric cancer screening rates.
- Provide wider access to innovative, non-invasive blood-based screening
- Reduce strain on hospitals and conventional screening facilities.

Unlike traditional screening methods like barium x-ray or endoscopy, GASTROClear™ offers a non invasive, fast, and physically gentle alternative, which is particularly beneficial for individuals with chronic conditions.

The broader collaboration will leverage Mirxes' proprietary blood-based miRNA test platforms, including GASTROClear™ and LUNGClear™, to build a comprehensive early cancer detection ecosystem in Japan. Nagawa Pharmaceutical's roles include localising the testing platforms, establishing a manufacturing system, and setting up the distribution network in the Japanese market. Its experience in technology transfer for PCR testing reagents, along with its "Japan Quality" manufacturing standards, will accelerate the deployment of Mirxes' technology and products in Japan.

This strategic partnership builds upon MirxesJapan's recent securing of a grant from the Japan External Trade Organization (JETRO) to develop and validate a new non-invasive cancer biomarker screening test service specifically for the Japanese market. It also represents a significant step in Mirxes' global expansion and its commitment to advancing preventive healthcare worldwide.